文献速递肿瘤 PET/CT

18F-DCFBC前列腺特异性膜抗原靶向PET/CT在局限性前列腺癌中的显像:与多参数MRI及组织病理学的相关性

18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.
PubMed 文献 · Clin Nucl Med · 2017-01-01

这项前瞻性研究纳入13例局限性前列腺癌患者,评估18F-DCFBC PSMA靶向PET/CT与多参数MRI(mpMRI)对照组织病理学检测病灶的能力。共25个肿瘤灶中,PET/CT与mpMRI对所有肿瘤的灵敏度分别为36%和96%,对索引病灶分别为61.5%和92%;原发前列腺癌平均SUVmax为5.8±4.4,高于良性前列腺增生结节(2.1±0.3)和正常前列腺组织(2.1±0.4)(P=0.0033)。作者认为多数索引前列腺癌可被18F-DCFBC PET/CT检出,但高灵敏度检测需联合mpMRI。

要点

  • 18F-DCFBC PET/CT对所有肿瘤灶灵敏度36%,对索引病灶61.5%。
  • mpMRI对所有肿瘤灶灵敏度96%,对索引病灶92%。
  • 原发前列腺癌SUVmax 5.8±4.4,高于良性增生结节2.1±0.3和正常组织2.1±0.4(P=0.0033)。

核心结论

  • 多数索引前列腺癌可被18F-DCFBC PET/CT检出,且可能基于摄取和分期成为预后指标。
  • 为高灵敏度检测前列腺癌,需将PSMA PET/CT与mpMRI联合。

研究设计与样本

  • 符合《1996年健康保险携带和责任法案》、经机构审查委员会批准的前瞻性研究,纳入13例可评估的局限性前列腺癌患者。
  • 患者中位年龄62.8岁(范围51-74岁),中位前列腺特异性抗原37.5 ng/dL(范围3.26-216 ng/dL)。
  • 患者在3个月窗口内接受mpMRI和18F-DCFBC PET/CT检查。
  • mpMRI所见病灶经直肠超声/MRI融合引导活检,或行根治性前列腺切除术。
  • 18F-DCFBC PET/CT与mpMRI分别盲法评估,以病灶为基础检测肿瘤;PET图像分析采用软件配准融合MRI与PET图像,影像所见与组织学相关,并以80%阈值SUVmax比较肿瘤与良性前列腺增生结节及正常外周带组织的摄取。

主要发现

  • 13例患者组织病理学共确认25个肿瘤灶(平均大小1.8 cm,中位大小1.5 cm,范围0.6-4.7 cm)。
  • 对所有肿瘤,18F-DCFBC PET/CT灵敏度36%,mpMRI灵敏度96%。
  • 对索引病灶(最大且Gleason评分最高的肿瘤),18F-DCFBC PET/CT灵敏度61.5%,mpMRI灵敏度92%。
  • 注射后1小时,原发前列腺癌平均SUVmax为5.8±4.4,高于良性前列腺增生结节的2.1±0.3和正常前列腺组织的2.1±0.4(P=0.0033)。

关键数值与推荐

  • PET图像分析采用80%阈值SUVmax。
  • 对所有肿瘤,18F-DCFBC PET/CT灵敏度36%,mpMRI灵敏度96%。
  • 对索引病灶,18F-DCFBC PET/CT灵敏度61.5%,mpMRI灵敏度92%。
  • 注射后1小时原发前列腺癌平均SUVmax 5.8±4.4,良性前列腺增生结节2.1±0.3,正常前列腺组织2.1±0.4(P=0.0033)。

临床怎么用

  • 作者认为多数索引前列腺癌可被18F-DCFBC PET/CT检出,且可能基于摄取和分期成为预后指标。
  • 作者指出,为高灵敏度检测前列腺癌,需将PSMA PET/CT与mpMRI联合。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the ability of (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-fluorobenzyl-L-cysteine) (F-DCFBC), a prostate-specific membrane antigen-targeted PET agent, to detect localized prostate cancer lesions in correlation with multiparametric MRI (mpMRI) and histopathology. METHODS: This Health Insurance Portability and Accountability Act of 1996-compliant, prospective, institutional review board-approved study included 13 evaluable patients with localized prostate cancer (median age, 62.8 years [range, 51-74 years]; median prostate-specific antigen, 37.5 ng/dL [range, 3.26-216 ng/dL]). Patients underwent mpMRI and F-DCFBC PET/CT within a 3 months' window. Lesions seen on mpMRI were biopsied under transrectal ultrasound/MRI fusion-guided biopsy, or a radical prostatectomy was performed. F-DCFBC PET/CT and mpMRI were evaluated blinded and separately for tumor detection on a lesion basis. For PET image analysis, MRI and F-DCFBC PET images were fused by using software registration; imaging findings were correlated with histology, and uptake of F-DCFBC in tumors was compared with uptake in benign prostatic hyperplasia nodules and normal peripheral zone tissue using the 80% threshold SUVmax. RESULTS: A total of 25 tumor foci (mean size, 1.8 cm; median size, 1.5 cm; range, 0.6-4.7 cm) were histopathologically identified in 13 patients. Sensitivity rates of F-DCFBC PET/CT and mpMRI were 36% and 96%, respectively, for all tumors. For index lesions, the largest tumor with highest Gleason score, sensitivity rates of F-DCFBC PET/CT and mpMRI were 61.5% and 92%, respectively. The average SUVmax for primary prostate cancer was higher (5.8 ± 4.4) than that of benign prostatic hyperplasia nodules (2.1 ± 0.3) or that of normal prostate tissue (2.1 ± 0.4) at 1 hour postinjection (P = 0.0033). CONCLUSIONS: The majority of index prostate cancers are detected with F-DCFBC PET/CT, and this may be a prognostic indicator based on uptake and staging. However, for detecting prostate cancer with high sensitivity, it is important to combine prostate-specific membrane antigen PET/CT with mpMRI.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Turkbey B, Mena E, Lindenberg L, et al. 18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology. Clin Nucl Med. 2017. PMID: 28806263. doi:10.1097/RLU.0000000000001804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。